Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcomes of Busulfan, Fludarabine, and 400 cGy Total Body Irradiation Compared With Busulfan and Fludarabine Reduced-Intensity Conditioning Regimens for Allogeneic Stem Cell Transplantation in Adult Patients With Hematologic Diseases: A Single-Center Experience.
Alkhaldi H, Goloubeva O, Rapoport AP, Dahiya S, Pang Y, Ali MM, Hardy NM, Mohindra P, Bukhari A, Lutfi F, Sanchez-Petitto G, Molitoris J, Samanta S, Li X, Toth T, Landau M, Hodges S, Nishioka J, Ruehle K, Ridge L, Gahres N, Kocoglu MH, Atanackovic D, Malinou JN, Yared JA. Alkhaldi H, et al. Among authors: kocoglu mh. Transplant Proc. 2023 Jan-Feb;55(1):214-224. doi: 10.1016/j.transproceed.2022.10.061. Epub 2023 Jan 11. Transplant Proc. 2023. PMID: 36635141
Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab.
Bathini S, Holtzman NG, Koka R, Singh Z, Wilding E, Zou Y, Ruehle K, Kocoglu MH, Badros A, Hardy N, Yared J, Rapoport AP, Fontaine M, Emadi A, El Chaer F, Dahiya S. Bathini S, et al. Among authors: kocoglu mh. Am J Hematol. 2019 Aug;94(8):E216-E219. doi: 10.1002/ajh.25515. Epub 2019 Jun 7. Am J Hematol. 2019. PMID: 31120638 Free article. No abstract available.
Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes.
Holtzman NG, Xie H, Bentzen S, Kesari V, Bukhari A, El Chaer F, Lutfi F, Siglin J, Hutnick E, Gahres N, Ruehle K, Ahmad H, Shanholtz C, Kocoglu MH, Badros AZ, Yared JA, Hardy NM, Rapoport AP, Dahiya S. Holtzman NG, et al. Among authors: kocoglu mh. Neuro Oncol. 2021 Jan 30;23(1):112-121. doi: 10.1093/neuonc/noaa183. Neuro Oncol. 2021. PMID: 32750704 Free PMC article. Review.
Chimeric antigen receptor T-cell therapy after allogeneic stem cell transplant for relapsed/refractory large B-cell lymphoma.
Lutfi F, Holtzman N, Siglin J, Bukhari A, Mustafa Ali M, Kim D, Sanchez-Petitto G, Gottlieb D, Ruehle K, Hutnick E, Gahres N, Hankey K, Lee S, Kocoglu M, Yared J, Hardy N, Rapoport A, Dahiya S. Lutfi F, et al. Br J Haematol. 2021 Jan;192(1):212-216. doi: 10.1111/bjh.17121. Epub 2020 Nov 10. Br J Haematol. 2021. PMID: 33169845 Free article. No abstract available.
The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma.
Lutfi F, Holtzman NG, Kansagra AJ, Mustafa Ali M, Bukhari A, Yan J, Samanta S, Gottlieb D, Kim DW, Matsumoto LR, Gahres N, Ruehle K, Lee ST, Law JY, Kocoglu MH, Atanackovic D, Yared JA, Hardy NM, Molitoris J, Mohindra P, Rapoport AP, Dahiya S. Lutfi F, et al. Among authors: kocoglu mh. Br J Haematol. 2021 Nov;195(3):405-412. doi: 10.1111/bjh.17738. Epub 2021 Sep 9. Br J Haematol. 2021. PMID: 34500492
34 results